revumenib + chemotherapy regimen 1

Revumenib + chemotherapy regimen 1 is a combination therapy consisting of **revumenib**, a first-in-class oral small molecule menin inhibitor developed for the treatment of acute leukemias with specific genetic mutations, and a defined chemotherapy regimen known as **chemotherapy regimen 1**. In a referenced clinical trial, "chemotherapy regimen 1" refers to standard induction chemotherapy for acute myeloid leukemia (AML) using **7 days of cytarabine and 3 days of daunorubicin**, commonly known as the "7+3" regimen. This combination may also include **midostaurin**, a multi-kinase (including FLT3) inhibitor, as per current clinical trials evaluating frontline therapy in newly diagnosed AML with NPM1 and FLT3 mutations. Revumenib targets the interaction between menin and MLL/KMT2A, affecting chromatin remodeling and gene expression to inhibit leukemic cell growth. This drug regimens aim to enhance remission rates and potentially deepen molecular responses in AML by leveraging both targeted therapy and cytotoxic chemotherapy[8].